Amgen: Biotech Giant's Path to Growth and Recovery
Amgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
A quick look at the safest stablecoins for newcomers, highlighting factors like reserve transparency and market liquidity.
19,229 articlesAmgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
A major defense buildup debate affects portfolios as lawmakers consider a 355-ship Navy. This article breaks down the...
When a beloved soap star hints at a fragile return, it isn’t just headlines that shake. It can ripple into budgets, i...
Can a meme-inspired token under $1 truly be a smart long-term buy? This guide breaks down the economics, risks, and r...
Asian companies are accelerating AI adoption as margins thin. This article outlines three ways that asia’s firms are ...
Trump signals a deal with Iran could be signed this weekend, but Tehran cautions that no final agreement exists. Medi...
As the AI era expands, investors are eyeing a broader landscape beyond Nvidia. This article explores a rising AI infr...
The first half of 2026 delivered a housing market that steadied into a new normal. Here are the five lessons that def...
Jeff Bezos argues that artificial intelligence will drive new job demand and skills need, potentially creating a labo...
Ford and GM are reshaping their business models by moving into energy-related assets like batteries, charging network...
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Robinhood stock soared from its spring lows, delivering a eye-catching rally. But a deeper look at revenue mix, regul...